A.R.T. Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

A.R.T. Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-19,096	Closed	-$158K	–	1278
2018 Q4	$158K	Buy	+19,096	New	+$196K	0.01%	1106

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

A.R.T. Advisors's ALDX Position: Q1 2019 in Review

A.R.T. Advisors sold out of Aldeyra Therapeutics (ALDX) in Q1 2019, closing a stake of 19,096 shares — an estimated $158K sold.

A.R.T. Advisors first reported a position in ALDX in Q4 2018 and held it in 1 quarter. The position peaked at $158K in Q4 2018. 79 funds tracked by Wall St. Rank hold ALDX as of Q1 2019.

A.R.T. Advisors reported no remaining Aldeyra Therapeutics position as of Q1 2019 after selling out during the quarter.
A.R.T. Advisors sold 19,096 Aldeyra Therapeutics shares in Q1 2019, an estimated $158K.
A.R.T. Advisors first reported a position in Aldeyra Therapeutics in Q4 2018 and held it in 1 quarter.
A.R.T. Advisors's Aldeyra Therapeutics position peaked at $158K in Q4 2018.
79 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2019.

Based on A.R.T. Advisors's 13F filing for Q1 2019, filed 15 May 2019.